Source: Market Watch
Shares of Novavax Inc. NVAX, 7.98% rallied 2.8% in premarket trading Thursday, after the biotechnology company said it has entered into a development and supply agreement with South Korea-based SK Group subsidiary SK Bioscience for the antigen component of Novavax’s COVID-19 vaccine candidate, NVX-CoV2373. The companies have also signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to make NVX-CoV2373 available in South Korea, as well as for the global market. Under terms of the agreement, SK Bioscience will make the vaccine antigen component during the pandemic period. Phase 1 data of Phase 1/2 clinical trial showed that NVX-CoV2373 was well tolerated and generated a “robust” antibody response. Novavax’s stock has more than tripled (up 205.9%) over the past three months through Wednesday, while the iShares Nasdaq Biotechnology ETF IBB, -0.16% has gained 3.3% and the S&P 500 SPX, 0.02% has advanced 19.9%.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE